BR100 Increased By (0.63%)
BR30 Increased By (0.86%)
KSE100 Increased By (0.68%)
KSE30 Increased By (0.74%)
AGHA 6.50 Increased By ▲ 0.12 (1.88%)
BECO 4.34 Decreased By ▼ -0.01 (-0.23%)
BML 62.25 Decreased By ▼ -0.30 (-0.48%)
BOP 31.50 Increased By ▲ 0.11 (0.35%)
CNERGY 11.84 Increased By ▲ 0.11 (0.94%)
CSIL 5.97 Increased By ▲ 0.06 (1.02%)
FCCL 61.75 Increased By ▲ 0.04 (0.06%)
FFL 14.87 Increased By ▲ 0.08 (0.54%)
FNEL 1.29 Increased By ▲ 0.05 (4.03%)
KEL 6.35 Increased By ▲ 0.03 (0.47%)
KOSM 5.91 Increased By ▲ 0.01 (0.17%)
LOTCHEM 24.88 Increased By ▲ 0.19 (0.77%)
MLCF 105.00 Increased By ▲ 1.07 (1.03%)
NBP 174.25 Increased By ▲ 0.93 (0.54%)
NCPL 52.10 Increased By ▲ 0.27 (0.52%)
NPL 54.51 Increased By ▲ 0.48 (0.89%)
OGDC 319.50 Increased By ▲ 3.63 (1.15%)
PACE 9.31 Increased By ▲ 0.05 (0.54%)
PAEL 36.00 Increased By ▲ 0.42 (1.18%)
PIBTL 13.78 Increased By ▲ 0.12 (0.88%)
PPL 228.10 Increased By ▲ 2.03 (0.9%)
PRL 81.10 Increased By ▲ 0.82 (1.02%)
PTC 47.24 Increased By ▲ 0.60 (1.29%)
SSGC 24.05 Increased By ▲ 0.23 (0.97%)
TBL 9.31 Increased By ▲ 0.07 (0.76%)
TELE 7.55 No Change ▼ 0.00 (0%)
TPL 25.00 Increased By ▲ 0.46 (1.87%)
TPLP 13.05 Increased By ▲ 0.06 (0.46%)
TREET 26.10 Increased By ▲ 0.12 (0.46%)
TRG 53.60 Increased By ▲ 0.27 (0.51%)
Business & Finance

Novartis raises annual sales guidance until 2028

Published Updated
By

FRANKFURT: Novartis on Thursday raised its medium-term sales guidance, predicting 6% annual growth through 2028, driven by strong momentum of launched drugs and the prospect of upcoming market introductions.

The Swiss drugmaker was previously targeting mid-term currency-adjusted sales growth of at least 5% from 2023 to 2028.

Novartis lifts 2024 guidance for third time on wider use of its drugs

It added that through the 2024-2029 period, it was still expecting 5% growth per year, given its strong performance in 2024.

Comments

Comments are closed for this article.